文献速递白血病

Ph阳性细胞附加染色体异常对慢性髓性白血病临床特征及预后的影响

[Analysis of clinical features and prognosis of patients with chronic myelogenous leukemia harboring additional chromosomal abnormalities in Ph-positive cells].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2021-01-01

该回顾性研究分析了410例Ph阳性慢性髓性白血病患者,按ELN2020标准分为高危、非高危和无附加染色体异常三组。初诊慢性期患者中附加染色体异常发生率为5.75%,非高危组5年无进展生存率显著低于无异常组。治疗中进展为加速期/急变期患者附加染色体异常发生率达66.13%,高危组完全细胞遗传学反应率和5年总生存率均显著低于无异常组。

要点

  • 初诊慢性期CML附加染色体异常发生率5.75%,非高危组5年PFS率42.0%显著低于无异常组74.5%。
  • 进展期CML附加染色体异常发生率66.13%,高危组5年OS率46.2%显著低于无异常组77.8%。
  • 高危Ⅱ组(-7/7q-、i(17q)或≥2个高危ACA复杂核型)5年OS率28.6%显著低于无异常组。

核心结论

  • 伴附加染色体异常的CML患者因ACA类型和疾病分期不同,治疗反应和预后存在差异。
  • 治疗过程中出现高危ACA意味着更差的治疗反应和预后。

研究设计与样本

  • 回顾性分析2013年1月至2020年6月河南省人民医院收治的410例Ph阳性CML患者。
  • 初诊CML-CP 348例,治疗中进展为CML-AP/BP 62例,按ELN2020标准分为高危、非高危和无ACA三组。

主要发现

  • 初诊CML-CP中ACA发生率5.75%(20/348),其中高危3例、非高危17例,无ACA 328例。
  • 非高危ACA组5年PFS率42.0%显著低于无ACA组74.5%(χ²=4.766,P=0.029)。
  • 进展期CML中ACA发生率66.13%(41/62),其中高危28例、非高危13例,无ACA 21例。
  • 高危ACA组CCyR率5.3%显著低于无ACA组46.7%(χ²=5.851,P=0.016)。
  • 高危ACA组5年OS率46.2%显著低于无ACA组77.8%(χ²=3.878,P=0.049)。

关键数值与推荐

  • 非高危ACA组与无ACA组CHR率、CCyR率、MMR率和5年OS率差异均无统计学意义(P值均>0.05)。
  • 高危ACA组中位PLT 42.5×10⁹/L低于非高危组141×10⁹/L和无ACA组109×10⁹/L(χ²=4.968,P=0.083)。
  • 三组间ABL激酶区点突变发生率差异无统计学意义(P=0.652)。
  • 高危Ⅱ组5年OS率28.6%显著低于无ACA组77.8%(χ²=8.035,P=0.005)。
  • 高危Ⅰ组5年OS率54.5%与无ACA组77.8%差异无统计学意义(χ²=1.514,P=0.219)。

临床怎么用

  • 对CML患者应进行严格、规范的细胞遗传学监测,以及时发现高危ACA。
  • 治疗中出现高危ACA提示疗效和预后更差,需尽早调整诊疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the effects of additional chromosomal abnormalities (ACA) in Philadelphia chromosome-positive (Ph(+)) cells on biological characteristics, therapy efficacy, and prognosis of patients with primary chronic myeloid leukemia (CML) -chronic phase (CP) and those who developed CML-accelerated phase/blast phase (AP/BP) during therapy. Methods: The clinical data of 410 patients with Ph(+) CML, including 348 patients with primary CML-CP and 62 patients who progressed to CML-AP/BP during treatment, who were admitted to Henan People's Hospital from January 2013 to June 2020 were retrospectively analyzed to categorize into high-risk, non-high-risk, and non-ACA groups according to the ELN2020 criteria. The effects of high- and non-high-risk ACA on biological characteristics, therapy efficacy, and prognosis were compared. Results: ①Among the 348 patients with primary CML-CP, 20 patients (5.75% ) had ACA, including 3 and 17 patients with high-risk and non-high-risk ACA, respectively, whereas the remaining 328 patients did not have ACA. There were no significant differences in baseline clinical characteristics between those with and without ACA (P>0.05 for all) . The rates of complete hematological response, complete cytogenetic response, major molecular remission, and 5-year overall survival (OS) were not significantly different between the non-high-risk ACA and non-ACA groups (P>0.05 for all) ; however, the 5-year progression-free survival of the non-high-risk ACA group (42.0% ) was significantly lower than that of the non-ACA group (74.5% ) (χ(2)=4.766, P=0.029) .②Of the 62 patients who progressed to CML-AP/BP during treatment, 41 patients (66.13% ) had ACA, including 28 and 13 patients with high-risk and non-high-risk ACA, respectively, whereas the remaining 21 patients did not have ACA. Platelet counts of the high-risk ACA group (42.5×10(9)/L) were lower than those of the non-high-risk (141×10(9)/L) and non-ACA groups (109×10(9)/L) (χ(2)=4.968, P=0.083) . There was no significant difference in the incidence of point mutations in ABL kinase among the three groups (P=0.652) . The complete cytogenetic response of the high-risk ACA group (5.3% ) was significantly lower than that of the non-ACA group (46.7% ) (χ(2)=5.851, P=0.016) . The 5-year OS of the high-risk ACA group was lower than that of the non-ACA group (46.2% vs 77.8% , χ(2)=3.878, P=0.049) . Subgroup analysis revealed that the 5-year OS rate of the high-risk group Ⅱ, which included -7/7q-, i (17q) , and complex karyotype comprising ≥2 high-risk ACA, was significantly lower than that of the non-ACA group (28.6% vs 77.8% , χ(2)=8.035, P=0.005) whereas the 5-year OS rate was not significantly different between high-risk group Ⅰ, which included +8,+Ph, and complex ACA with +8/+Ph, and the non-ACA group (54.5% vs 77.8% , χ(2) =1.514, P=0.219) . Conclusion: Due to different disease stages and ACA/Ph(+) types, treatment response and prognosis vary among patients with CML harboring ACA/Ph(+). The emergence of high-risk ACA during therapy suggests worse therapy efficacy and prognosis. Strict and standardized cytogenetic monitoring is critical for early detection, precise diagnosis, and treatment of these patients. 目的: 探讨Ph阳性附加染色体异常(ACA/Ph(+))对初诊慢性期(CP)和治疗中进展为加速期和急变期慢性髓性白血病(CML-AP/BP)患者生物学特征、疗效和预后的影响。 方法: 回顾性分析2013年1月至2020年6月河南省人民医院收治的410例Ph(+) CML[初诊CML-CP 348例,治疗中进展为AP/BP(进展期CML)62例]患者的临床资料,根据ELN2020标准将其分为高危、非高危和无ACA/Ph(+)三组,并比较分析高危/非高危ACA/Ph(+)对其生物学特征、疗效和预后的影响。 结果: ①348例初诊CML-CP患者,合并ACA/Ph(+)者20例(5.75%),其中高危ACA/Ph(+)组3例,非高危ACA/Ph(+)组17例;无ACA/Ph(+)组328例。伴ACA/Ph(+)和无ACA/Ph(+)组患者的基本临床特征差异无统计学意义(P值均>0.05);非高危ACA/Ph(+)组和无ACA/Ph(+)组间完全血液学缓解(CHR)率、完全细胞遗传学反应(CCyR)率、主要分子学反应(MMR)率和5年总生存(OS)率差异均无统计学意义(P值均>0.05);非高危ACA/Ph(+)组5年无进展生存(PFS)率显著低于无ACA/Ph(+)组(42.0%对74.5%,χ(2)=4.766,P=0.029)。②62例进展期CML患者,合并ACA/Ph(+)者41例(66.13%),其中高危ACA/Ph(+)组28例,非高危ACA/Ph(+)组13例;无ACA/Ph(+)组21例。高危ACA/Ph(+)组患者中位PLT水平(42.5×10(9)/L)低于非高危(141×10(9)/L)和无ACA/Ph(+)组(109×10(9)/L)(χ(2)=4.968,P=0.083);三组间ABL激酶区点突变发生率差异无统计学意义(P=0.652)。高危ACA/Ph(+)组CCyR率显著低于无ACA/Ph(+)组(5.3%对46.7%,χ(2)=5.851,P=0.016)。高危ACA/Ph(+)组5年OS率为46.2%,非高危ACA/Ph(+)组为64.3%,无ACA/Ph(+)组为77.8%,其中高危ACA/Ph(+)组患者5年OS率明显低于无ACA/Ph(+)组(χ(2)=3.878,P=0.049)。亚组分析显示高危Ⅰ组(+8,+Ph或含+8/+Ph的复杂ACA)CML患者的5年OS率为54.5%,与无ACA/Ph(+)组相比差异无统计学意义(χ(2)=1.514,P=0.219);高危Ⅱ组[含-7/7q-或i(17q)或含2个及以上高危ACA的复杂核型]为28.6%,显著低于无ACA/Ph(+)组(χ(2)=8.035,P=0.005)。 结论: 因ACA类型和疾病分期不同,伴ACA/Ph(+) CML患者的治疗反应和预后存在差异,治疗过程中高危ACA的出现意味着更差的治疗反应和预后,严格、规范的细胞遗传学监测对此类患者的早期发现和精准诊疗具有重要意义。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Dong XY, Li YL, Wu CY, et al. [Analysis of clinical features and prognosis of patients with chronic myelogenous leukemia harboring additional chromosomal abnormalities in Ph-positive cells]. Zhonghua Xue Ye Xue Za Zhi. 2021. PMID: 34547872. doi:10.3760/cma.j.issn.0253-2727.2021.08.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。